查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046213

結核病治療市場－全球產業規模、佔有率、趨勢、機會與預測：依疾病類型、療法、給藥途徑、劑型、通路、地區、競爭格局分類，2021-2031年

Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Disease Type, By Therapy, By Route of Administration, By Dosage Form, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球結核病治療市場預計將從 2025 年的 22.7 億美元成長到 2031 年的 31.4 億美元，複合年成長率達到 5.56%。

該市場專注於治療活動性及潛伏性病菌感染的藥物（包括第一線和二線藥物）的商業化和分銷。其主要促進因素是多重抗藥性菌株在全球範圍內持續肆虐，以及世界衛生組織為根除結核病提供的持續資金支持。這些因素確立了基本需求，並確保了穩定的供應，尤其是在政府採購占主導地位的高負擔地區。

市場概覽
預測期 2027-2031
市場規模：2025年 22.7億美元
市場規模：2031年 31.4億美元
複合年成長率：2026-2031年 5.56%
成長最快的細分市場 口服
最大的市場 中東和非洲

市場促進因素

該市場的主要驅動力是多重抗藥性結核病（MDR-TB）的日益普及。隨著對第一線標準抗生素的抗藥性不斷擴散，全球對先進的二線療法和聯合療法的需求也不斷成長。例如，世界衛生組織報告稱，到2023年將有40萬人患有多重抗藥性/利福平抗藥性結核病（MDR/RR-TB），迫使各國衛生計畫引入專門的治療方法。同時，諸如BPaL（貝達喹啉、普瑞托馬尼、Linezolid）等療程更短、療效更佳的全口服治療方法的引入，正在改變臨床方案，並加速創新治療方法的應用。從長期注射治療轉向簡化的口服治療顯著提高了患者的依從性和臨床成功率，促使衛生部門迅速採納。因此，全球耐多藥/利福平抗藥性結核病的治療成功率已上升至68%。這種廣泛應用得到了全球基金等組織的支持，該組織在2023年治療了創紀錄的710萬名結核病患者。這表明對這種治療的需求非常高。

市場挑戰

然而，長期資金短缺嚴重阻礙了市場擴張。這限制了國家衛生計畫採購和分發基本抗生素方案的能力，擾亂了供應鏈，並降低了製藥公司投資研發新療法的獎勵。資金短缺導致產品平臺停滯不前，尤其是結核病高發生率。這些地區高度依賴外部捐贈資金，被迫使用過時的藥物，因為2024年全球結核病防治資金僅57億美元，遠低於全球需求。這種持續的資金缺口最終限制了藥物研發公司的潛在市場規模和收入前景。

市場趨勢

儘管面臨這些挑戰，市場中正湧現變革性趨勢。例如，適用於兒童的可分散固定劑量組合藥物的創新應用。這些製劑劑量精準、服用方便，提高了兒童患者的用藥遵從性和生物利用度。 2023年，兒童結核病報告病例數達到創紀錄的70萬例。此外，人工智慧（AI）在抗結核藥物研發的應用正在革新研發流程。透過利用生成式人工智慧模型和機器學習演算法來高效識別新型化合物和藥物標靶，早期藥物研發進程得以加速，從而能夠開發出可以繞過現有抗藥性機制的新型抗生素。利用生成式人工智慧成功辨識出有前景的化合物的案例便證明了這一點。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球結核病治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 疾病類型（活動性結核病、潛伏性結核病）
    • 依治療類型分類的治療（第一線治療、二線治療）
    • 給藥途徑（口服、腸外、其他）
    • 劑型（錠劑、膠囊、注射劑、其他）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美結核病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲結核病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區結核病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲結核病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲結核病治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球結核病治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AstraZeneca PLC
  • Johnson & Johnson Services, Inc.
  • Eli Lilly and Company
  • Mylan Inc.
  • Teva Pharmaceutical Industries Ltd
  • Sanofi SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Pfizer Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 14842

The Global Tuberculosis Therapeutics Market is projected to grow from USD 2.27 Billion in 2025 to USD 3.14 Billion by 2031, achieving a Compound Annual Growth Rate of 5.56%. This market focuses on the commercialization and distribution of pharmacological agents, including first-line and second-line antibiotics, for treating active and latent Mycobacterium tuberculosis infections. It is primarily propelled by the persistent global burden of multi-drug resistant strains and sustained financial commitments from international health organizations aimed at disease eradication, which establish a foundational demand and ensure stable procurement, especially in high-burden regions dominated by government purchasing.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.27 Billion
Market Size 2031USD 3.14 Billion
CAGR 2026-20315.56%
Fastest Growing SegmentOral
Largest MarketMiddle East & Africa

Market Driver

The market is significantly driven by the increasing prevalence of Multi-Drug Resistant Tuberculosis (MDR-TB), which heightens the global demand for advanced second-line and combinatorial treatments as resistance to standard first-line antibiotics expands. For instance, the WHO reported 400,000 people developed MDR/RR-TB in 2023, compelling national health programs to acquire specialized regimens. Simultaneously, the introduction of shorter and more effective all-oral treatment regimens, such as BPaL (bedaquiline, pretomanid, and linezolid), is transforming clinical protocols and boosting the adoption of innovative therapies. The shift from lengthy, injectable courses to streamlined oral regimens markedly improves patient adherence and clinical success rates, leading to rapid uptake by healthcare authorities, with the global MDR/RR-TB treatment success rate rising to 68%. This widespread deployment is supported by organizations like the Global Fund, which treated a record 7.1 million people for tuberculosis in 2023, indicating substantial therapeutic volume requirements.

Market Challenge

However, the market's expansion is significantly hindered by chronic underfunding, which restricts national health programs' capacity to procure and distribute essential antibiotic regimens, disrupting supply chains and diminishing incentives for pharmaceutical companies to invest in novel therapeutics. This financial deficit results in a stagnant product pipeline, particularly affecting high-burden regions where dependence on external donor funding leads to reliance on older medications, as only US$ 5.7 billion was available for TB services in 2024, far short of global requirements. This persistent gap consequently limits the addressable market and revenue prospects for therapeutic developers.

Market Trends

Despite these challenges, the market is witnessing transformative trends, including innovation in pediatric-friendly dispersible fixed-dose combinations that offer precise, palatable formulations, improving adherence and bioavailability for young patients-a demographic with a record 700,000 children notified with TB in 2023. Additionally, the integration of Artificial Intelligence in anti-tubercular drug discovery is revolutionizing the R&D pipeline, with generative models and machine learning algorithms being leveraged to efficiently identify novel chemical entities and drug targets, thereby accelerating early-stage discovery and enabling the development of new antibiotic classes capable of circumventing existing resistance mechanisms, as demonstrated by successful initiatives using generative AI to identify promising compounds.

Key Market Players

  • AstraZeneca PLC
  • Johnson & Johnson Services, Inc.
  • Eli Lilly and Company
  • Mylan Inc.
  • Teva Pharmaceutical Industries Ltd
  • Sanofi S.A.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Pfizer Inc.

Report Scope

In this report, the Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tuberculosis Therapeutics Market, By Disease Type

  • Active TB
  • Latent TB

Tuberculosis Therapeutics Market, By Therapy

  • First-Line Therapy
  • Second-Line Therapy

Tuberculosis Therapeutics Market, By Route of Administration

  • Oral
  • Parenteral
  • Others

Tuberculosis Therapeutics Market, By Dosage Form

  • Tablets
  • Capsules
  • Injection
  • Others

Tuberculosis Therapeutics Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Tuberculosis Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tuberculosis Therapeutics Market.

Available Customizations:

Global Tuberculosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tuberculosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Active TB, Latent TB)
    • 5.2.2. By Therapy (First-Line Therapy, Second-Line Therapy)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.4. By Dosage Form (Tablets, Capsules, Injection, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Tuberculosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Therapy
    • 6.2.3. By Route of Administration
    • 6.2.4. By Dosage Form
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Tuberculosis Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Therapy
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Dosage Form
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Tuberculosis Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Therapy
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Dosage Form
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Tuberculosis Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Therapy
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Dosage Form
        • 6.3.3.2.5. By Distribution Channel

7. Europe Tuberculosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Therapy
    • 7.2.3. By Route of Administration
    • 7.2.4. By Dosage Form
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Tuberculosis Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Therapy
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Dosage Form
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. France Tuberculosis Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Therapy
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Dosage Form
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Tuberculosis Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Therapy
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Dosage Form
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Tuberculosis Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Therapy
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Dosage Form
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Tuberculosis Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Therapy
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Dosage Form
        • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Tuberculosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Therapy
    • 8.2.3. By Route of Administration
    • 8.2.4. By Dosage Form
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Tuberculosis Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Therapy
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Dosage Form
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Tuberculosis Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Therapy
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Dosage Form
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Tuberculosis Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Therapy
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Dosage Form
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Tuberculosis Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Therapy
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Dosage Form
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Tuberculosis Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Therapy
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Dosage Form
        • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Tuberculosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Therapy
    • 9.2.3. By Route of Administration
    • 9.2.4. By Dosage Form
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Tuberculosis Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Therapy
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Dosage Form
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. UAE Tuberculosis Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Therapy
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Dosage Form
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. South Africa Tuberculosis Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Therapy
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Dosage Form
        • 9.3.3.2.5. By Distribution Channel

10. South America Tuberculosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Therapy
    • 10.2.3. By Route of Administration
    • 10.2.4. By Dosage Form
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Tuberculosis Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Therapy
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Dosage Form
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Colombia Tuberculosis Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Therapy
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Dosage Form
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Argentina Tuberculosis Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Therapy
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Dosage Form
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Tuberculosis Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AstraZeneca PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Johnson & Johnson Services, Inc.
  • 15.3. Eli Lilly and Company
  • 15.4. Mylan Inc.
  • 15.5. Teva Pharmaceutical Industries Ltd
  • 15.6. Sanofi S.A.
  • 15.7. Novartis AG
  • 15.8. Sun Pharmaceutical Industries Ltd
  • 15.9. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer